UBS made no change to the firm’s Neutral rating or $66 price target on Exact Sciences following the FDA’s advisory committee on multi-cancer detection tests. The firm believes the FDA panel favored having a tissue of origin signal as a required feature of an MCD test, which Exact’s Cancerguard does not, and says Exact must convince the community both of the benefits of its test approach without a tissue of origin signal as well as the potential benefits of trading 1 point of specificity for greater sensitivity, or redesign its test, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXAS:
- Exact Sciences files patent infringement lawsuit against Geneoscopy
- Exact Sciences price target lowered to $88 from $106 at Craig-Hallum
- Exact Sciences price target lowered to $95 from $110 at Jefferies
- Exact Sciences price target lowered to $100 from $120 at TD Cowen
- Exact Sciences sees FY23 revenue $2.476B-$2.486B, consensus $2.46B